Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 157437, 6 pages
http://dx.doi.org/10.1100/2012/157437
Clinical Study

The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients

1School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
2Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan
3Division of Nephrology, Department of Medicine, Taipei City Hospital, Zhong-Xing Branch, Taipei 103, Taiwan
4Division of Nephrology, Department of Medicine, Taipei City Hospital, Zhong-Xing Branch, Taipei 115, Taiwan
5Division of Nephrology, Department of Medicine, Taipei Medical Univeristy Hospital, Taipei 110, Taiwan
6Department of Medicine, School of Medicine, College of Medicine, Taipei Medical Univeristy, Taipei 110, Taiwan

Received 2 November 2011; Accepted 5 December 2011

Academic Editor: Biagio R. Di Iorio

Copyright © 2012 Wen-Sheng Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Tarng, “Cardiorenal anemia syndrome in chronic kidney disease,” Journal of the Chinese Medical Association, vol. 70, no. 10, pp. 424–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. Eschbach, “Erythropoietin 1991—an overview,” American Journal of Kidney Diseases, vol. 18, no. 4, pp. 3–9, 1991. View at Google Scholar · View at Scopus
  3. K. Yong and L. Kairaitis, “Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort,” Nephrology, vol. 15, no. 3, pp. 288–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. K. Chiang, S. Y. Yang, Y. S. Peng et al., “Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects,” American Journal of Nephrology, vol. 29, no. 5, pp. 392–397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Ranchon, S. Hédoux, M. Laville et al., “Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review,” Nephrologie et Therapeutique, vol. 6, no. 2, pp. 97–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Topf, “CERA: third-generation erythropoiesis-stimulating agent,” Expert Opinion on Pharmacotherapy, vol. 9, no. 5, pp. 839–849, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Chanu, R. Gieschke, J. E. Charoin, A. Pannier, and B. Reigner, “Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-Naïve and ESA-Treated chronic kidney disease patients with renal anemia,” Journal of Clinical Pharmacology, vol. 50, no. 5, pp. 507–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. H. H. Chen, D. C. Tarng, K. F. Lee, C. J. Wu, and Y. C. Chen, “Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease,” Journal of Nephrology, vol. 21, no. 4, pp. 543–549, 2008. View at Google Scholar · View at Scopus
  9. M. Loo and Y. Beguin, “The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply,” Blood, vol. 93, no. 10, pp. 3286–3293, 1999. View at Google Scholar · View at Scopus
  10. A. Sharma, K. Vanderhalt, K. J. Ryan, and J. Sclafani, “Refining the approach to IV iron use in hemodialysis patients: a post-DRIVE analysis,” Nephrology News & Issues, vol. 24, no. 4, pp. 29–35, 2010. View at Google Scholar · View at Scopus
  11. D. C. Tarng, T. W. Chen, and T. P. Huang, “Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients,” American Journal of Nephrology, vol. 15, no. 3, pp. 230–237, 1995. View at Google Scholar · View at Scopus
  12. J. Elliott, D. Mishler, and R. Agarwal, “Hyporesponsiveness to erythropoietin: causes and management,” Advances in Chronic Kidney Disease, vol. 16, no. 2, pp. 94–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Kanbay, M. A. Perazella, B. Kasapoglu, M. Koroglu, and A. Covic, “Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management,” Blood Purification, vol. 29, no. 1, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Del Vecchio, P. Pozzoni, S. Andrulli, and F. Locatelli, “Inflammation and resistance to treatment with recombinant human erythropoietin,” Journal of Renal Nutrition, vol. 15, no. 1, pp. 137–141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Caregaro, L. Di Pascoli, A. Favaro, M. Nardi, and P. Santonastaso, “Sodium depletion and hemoconcentration: overlooked complications in patients with anorexia nervosa?” Nutrition, vol. 21, no. 4, pp. 438–445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. C. C. Lin, X. M. Liu, K. Peyton et al., “Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 4, pp. 739–745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. E. Rancourt, M. E. Rodrigue, M. Agharazii, R. Larivière, and M. Lebel, “Role of oxidative stress in erythropoietin-induced hypertension in uremic rats,” American Journal of Hypertension, vol. 23, no. 3, pp. 314–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Shalev, J. Kapelushnik, A. Moser, H. Knobler, and H. Tamary, “Hypocholesterolemia in chronic anemias with increased erythropoietic activity,” American Journal of Hematology, vol. 82, no. 3, pp. 199–202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Kojuri, A. Karimi, N. Pourafshar, and A. R. Vosoughi, “Association between serum levels Of Hs-CRP and LDL-C with degree of coronary artery stenosis in patients with stable angina pectoris,” Iranian Red Crescent Medical Journal, vol. 12, no. 4, pp. 396–405, 2010. View at Google Scholar · View at Scopus
  20. V. Teplan Jr., F. Vyhnánek, R. Gürlich et al., “Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease,” Wiener Klinische Wochenschrift, vol. 122, no. 15-16, pp. 466–473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Ertürk, G. Nergizoǧlu, K. Ateş et al., “The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 14, no. 8, pp. 1912–1916, 1999. View at Publisher · View at Google Scholar
  22. M. O. Ogunniyi, J. B. Croft, K. J. Greenlund, W. H. Giles, and G. A. Mensah, “Racial/ethnic differences in microalbuminuria among adults with prehypertension and hypertension: national Health and Nutrition Examination Survey (NHANES), 1999–2006,” American Journal of Hypertension, vol. 23, no. 8, pp. 859–864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Locatelli, S. Andrulli, B. Memoli et al., “Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 21, no. 4, pp. 991–998, 2006. View at Publisher · View at Google Scholar · View at Scopus